

Cancer prevalence projections in the UK from 2025 to 2045: data tables

Data tables by nation, cancer type, sex and age at index date

August 2026

About this publication

These tables present modelled projections of the number of people living with cancer in the UK and its constituent nations, from 2025 to 2045. They provide a comprehensive set of breakdowns to support analysis, planning and further research.

This document is part of a wider project and is designed to be used alongside the main project report, which summarises the key findings, and the full methodology document, which explains the modelling approach in detail. The numbers in this document differ slightly to those in the main report. This is a result of a minor refinement and improvement to the methods following the publication of the main report.

Main report: [Living with and beyond cancer in 2045: see the future, support the people](#).

Methodology: [Cancer Prevalence Projections to 2045: Technical Methodology](#)

Overview of the project

This project was undertaken by Macmillan Cancer Support in partnership with Scottish Widows. The aim was to produce projections of complete prevalence that should complement time-limited prevalence estimates published by the cancer registries in the UK. The guiding principles of the modelling approach included to:

- Produce prevalence estimates using a consistent set of age groups and cancer type definitions across England, Scotland, Wales and Northern Ireland.
- Estimate complete prevalence - the number of people alive who have ever been diagnosed with cancer.
- Develop forward-looking projections of prevalence up to 2045, based on observed trends in cancer incidence and survival.
- Construct the model exclusively using publicly available, aggregated and non-identifiable data.
- Formulate projections based on the assumption that recently observed trends in incidence and survival would continue.

Interpreting these statistics

This document intentionally provides only a high-level description of the modelling approach. For full details, including data sources, modelling methods, assumptions and limitations please refer to the full methodology document:

[Cancer Prevalence Projections to 2045: Technical Methodology](#)

Projections and uncertainty

Figures for recent and future years are modelled estimates, not observed data. They are based on the assumption that:

- recent trends in incidence and survival continue into the future
- population projections are realised as anticipated

As with all projections, actual future prevalence may differ.

Comparisons between nations

Estimates are produced separately for each UK nation using consistent definitions wherever possible. However:

- granularity of data in underlying incidence and survival datasets, such as age banding and cancer groups, vary significantly
- gaps in available data, such as certain years or certain cancer sites, varied across datasets
- modelling adjustments are applied independently

For this reason, differences in projected growth between nations should not be interpreted as precise like-for-like comparisons. Some between nations differences in projections are the result of artefacts of differences in model assumptions rather than genuine differences in projections.

Rounding and precision

All prevalence projections are presented here as rounded to 2 significant figures. Projections below 500 have been suppressed. Small differences between totals and the sum of components may occur due to rounding.

Breakdowns by sex/gender and inclusive language

The figures in these tables are derived from published health datasets that classify individuals as male or female according to the recording practices and processing rules in place at the time. These datasets do not consistently distinguish between sex assigned at birth and gender identity and only include binary categories. In some outputs, the figures from these tables may be described using the terms 'men and people assigned male at birth' and 'women and people assigned female at birth' to use inclusive language, and in others they may be described using 'men' and 'women', however the underlying data used for both types of wording is the same. The methodology document contains further information and guidance for interpreting these statistics.

UK - Persons - All ages	Complete cancer prevalence					5-year prevalence				
	2025	2030	2035	2040	2045	2025	2030	2035	2040	2045
All cancers combined	3,500,000	4,000,000	4,500,000	5,000,000	5,400,000	1,400,000	1,600,000	1,800,000	1,900,000	2,000,000
Female breast	920,000	1,000,000	1,200,000	1,300,000	1,400,000	280,000	310,000	340,000	360,000	380,000
Prostate	610,000	740,000	880,000	1,000,000	1,100,000	240,000	290,000	340,000	370,000	390,000
Colorectal	390,000	440,000	490,000	540,000	590,000	160,000	170,000	190,000	200,000	210,000
Melanoma	270,000	330,000	410,000	490,000	560,000	93,000	120,000	140,000	160,000	170,000
Haematology	360,000	410,000	470,000	520,000	570,000	120,000	140,000	160,000	170,000	180,000
Gynaecology	320,000	360,000	400,000	440,000	480,000	92,000	100,000	110,000	120,000	130,000
Head and neck	180,000	220,000	260,000	310,000	350,000	65,000	77,000	89,000	99,000	110,000
Lung	140,000	160,000	190,000	220,000	240,000	91,000	110,000	120,000	130,000	140,000
Urology, excl prostate	270,000	310,000	350,000	380,000	420,000	96,000	110,000	120,000	130,000	140,000
Upper GI	120,000	140,000	160,000	180,000	200,000	68,000	78,000	88,000	95,000	100,000
Brain/CNS	49,000	56,000	63,000	70,000	76,000	15,000	17,000	19,000	20,000	20,000
Sarcoma	47,000	52,000	56,000	60,000	64,000	11,000	12,000	14,000	15,000	16,000

UK - Female - All ages	Complete cancer prevalence					5-year prevalence				
	2025	2030	2035	2040	2045	2025	2030	2035	2040	2045
All cancers combined	2,000,000	2,200,000	2,500,000	2,800,000	3,000,000	710,000	820,000	920,000	990,000	1,100,000
Female breast	920,000	1,000,000	1,200,000	1,300,000	1,400,000	280,000	310,000	340,000	360,000	380,000
Colorectal	180,000	210,000	240,000	270,000	300,000	74,000	83,000	92,000	100,000	110,000
Melanoma	150,000	190,000	220,000	260,000	300,000	47,000	58,000	68,000	76,000	81,000
Haematology	160,000	180,000	210,000	230,000	260,000	52,000	60,000	69,000	75,000	80,000
Gynaecology	320,000	360,000	400,000	440,000	480,000	92,000	100,000	110,000	120,000	130,000
Head and neck	100,000	130,000	150,000	180,000	200,000	33,000	40,000	46,000	50,000	54,000
Lung	80,000	100,000	130,000	150,000	170,000	52,000	65,000	78,000	87,000	92,000
Urology, excl prostate	66,000	77,000	88,000	100,000	110,000	26,000	30,000	34,000	38,000	40,000
Upper GI	50,000	59,000	68,000	76,000	84,000	27,000	31,000	35,000	38,000	40,000
Brain/CNS	23,000	26,000	29,000	32,000	35,000	6,800	7,400	8,000	8,500	8,800
Sarcoma	29,000	32,000	35,000	38,000	41,000	6,800	7,700	8,600	9,300	9,800

UK - Male - All ages	Complete cancer prevalence					5-year prevalence				
	2025	2030	2035	2040	2045	2025	2030	2035	2040	2045
All cancers combined	1,500,000	1,700,000	2,000,000	2,200,000	2,400,000	650,000	760,000	860,000	940,000	990,000
Prostate	610,000	740,000	880,000	1,000,000	1,100,000	240,000	290,000	340,000	370,000	390,000
Colorectal	210,000	230,000	250,000	270,000	280,000	85,000	90,000	97,000	100,000	110,000
Melanoma	120,000	150,000	190,000	220,000	260,000	46,000	60,000	73,000	84,000	92,000
Haematology	200,000	230,000	260,000	290,000	310,000	68,000	79,000	90,000	99,000	100,000
Head and neck	81,000	96,000	110,000	130,000	150,000	32,000	38,000	43,000	48,000	52,000
Lung	60,000	63,000	66,000	70,000	73,000	39,000	42,000	44,000	46,000	48,000
Urology, excl prostate	210,000	230,000	260,000	280,000	310,000	70,000	79,000	87,000	94,000	99,000
Upper GI	71,000	83,000	94,000	110,000	110,000	41,000	47,000	53,000	57,000	60,000
Brain/CNS	26,000	30,000	34,000	37,000	41,000	8,700	9,700	11,000	11,000	12,000
Sarcoma	18,000	19,000	21,000	22,000	23,000	4,400	4,700	5,100	5,400	5,700

UK - All cancers combined		Complete cancer prevalence					5-year prevalence				
		2025	2030	2035	2040	2045	2025	2030	2035	2040	2045
Female	0-39	79,000	82,000	85,000	88,000	90,000	40,000	43,000	45,000	46,000	48,000
	40-49	130,000	140,000	160,000	160,000	160,000	61,000	69,000	77,000	80,000	79,000
	50-59	290,000	300,000	320,000	360,000	390,000	130,000	130,000	140,000	160,000	170,000
	60-69	470,000	560,000	590,000	600,000	640,000	180,000	220,000	230,000	230,000	240,000
	70-79	560,000	610,000	740,000	850,000	890,000	180,000	200,000	240,000	270,000	270,000
	80-89	370,000	470,000	520,000	590,000	710,000	110,000	140,000	150,000	170,000	200,000
	90+	71,000	89,000	120,000	150,000	170,000	20,000	23,000	30,000	37,000	40,000
Male	0-39	60,000	63,000	66,000	68,000	69,000	26,000	28,000	29,000	30,000	31,000
	40-49	63,000	70,000	76,000	81,000	84,000	25,000	29,000	33,000	36,000	37,000
	50-59	150,000	160,000	180,000	200,000	220,000	80,000	87,000	96,000	110,000	120,000
	60-69	320,000	380,000	420,000	430,000	460,000	170,000	200,000	220,000	220,000	230,000
	70-79	500,000	550,000	650,000	750,000	780,000	220,000	250,000	290,000	330,000	330,000
	80-89	330,000	430,000	480,000	540,000	650,000	120,000	150,000	160,000	180,000	210,000
	90+	51,000	67,000	91,000	120,000	130,000	15,000	18,000	24,000	30,000	33,000
Persons	0-39	140,000	140,000	150,000	160,000	160,000	66,000	71,000	74,000	77,000	78,000
	40-49	190,000	210,000	230,000	240,000	250,000	86,000	99,000	110,000	120,000	120,000
	50-59	450,000	460,000	500,000	560,000	610,000	210,000	220,000	240,000	270,000	290,000
	60-69	800,000	940,000	1,000,000	1,000,000	1,100,000	350,000	420,000	450,000	450,000	470,000
	70-79	1,100,000	1,200,000	1,400,000	1,600,000	1,700,000	400,000	450,000	540,000	600,000	600,000
	80-89	700,000	890,000	1,000,000	1,100,000	1,400,000	220,000	280,000	320,000	350,000	410,000
	90+	120,000	160,000	210,000	270,000	300,000	34,000	41,000	54,000	67,000	72,000

England - Persons - All ages	Complete cancer prevalence					5-year prevalence				
	2025	2030	2035	2040	2045	2025	2030	2035	2040	2045
All cancers combined	2,900,000	3,300,000	3,800,000	4,200,000	4,600,000	1,100,000	1,300,000	1,500,000	1,600,000	1,700,000
Female breast	770,000	870,000	980,000	1,100,000	1,200,000	230,000	260,000	290,000	310,000	320,000
Prostate	510,000	620,000	730,000	850,000	960,000	200,000	250,000	280,000	310,000	330,000
Colorectal	320,000	360,000	410,000	450,000	480,000	130,000	140,000	160,000	170,000	180,000
Melanoma	220,000	280,000	340,000	410,000	470,000	78,000	99,000	120,000	130,000	150,000
Haematology	300,000	350,000	400,000	440,000	490,000	100,000	120,000	140,000	150,000	160,000
Gynaecology	270,000	300,000	340,000	370,000	400,000	77,000	87,000	97,000	100,000	110,000
Head and neck	150,000	190,000	220,000	260,000	300,000	55,000	66,000	77,000	86,000	92,000
Lung	110,000	130,000	150,000	180,000	190,000	74,000	87,000	99,000	110,000	110,000
Urology, excl prostate	230,000	260,000	290,000	330,000	360,000	82,000	93,000	100,000	110,000	120,000
Upper GI	100,000	120,000	140,000	150,000	170,000	57,000	65,000	73,000	79,000	84,000
Brain/CNS	42,000	48,000	54,000	60,000	65,000	13,000	15,000	16,000	17,000	18,000
Sarcoma	40,000	44,000	48,000	51,000	55,000	9,500	11,000	12,000	13,000	13,000

England - Female - All ages	Complete cancer prevalence					5-year prevalence				
	2025	2030	2035	2040	2045	2025	2030	2035	2040	2045
All cancers combined	1,600,000	1,900,000	2,100,000	2,300,000	2,600,000	600,000	690,000	770,000	840,000	880,000
Female breast	770,000	870,000	980,000	1,100,000	1,200,000	230,000	260,000	290,000	310,000	320,000
Colorectal	150,000	170,000	200,000	220,000	250,000	61,000	69,000	76,000	82,000	88,000
Melanoma	120,000	150,000	190,000	220,000	250,000	39,000	49,000	57,000	64,000	69,000
Haematology	140,000	160,000	180,000	200,000	220,000	44,000	52,000	59,000	64,000	68,000
Gynaecology	270,000	300,000	340,000	370,000	400,000	77,000	87,000	97,000	100,000	110,000
Head and neck	87,000	110,000	130,000	150,000	170,000	28,000	34,000	39,000	43,000	46,000
Lung	64,000	81,000	100,000	120,000	130,000	42,000	53,000	63,000	71,000	75,000
Urology, excl prostate	55,000	65,000	75,000	85,000	94,000	22,000	26,000	29,000	32,000	34,000
Upper GI	42,000	49,000	57,000	64,000	70,000	23,000	26,000	29,000	32,000	34,000
Brain/CNS	20,000	23,000	25,000	28,000	31,000	5,900	6,500	7,000	7,400	7,700
Sarcoma	25,000	28,000	30,000	33,000	35,000	5,800	6,600	7,400	8,000	8,500

England - Male - All ages	Complete cancer prevalence					5-year prevalence				
	2025	2030	2035	2040	2045	2025	2030	2035	2040	2045
All cancers combined	1,200,000	1,400,000	1,600,000	1,800,000	2,000,000	540,000	630,000	720,000	790,000	840,000
Prostate	510,000	620,000	730,000	850,000	960,000	200,000	250,000	280,000	310,000	330,000
Colorectal	170,000	190,000	210,000	220,000	240,000	71,000	75,000	81,000	85,000	89,000
Melanoma	97,000	130,000	160,000	190,000	220,000	38,000	50,000	61,000	70,000	77,000
Haematology	170,000	190,000	220,000	240,000	270,000	58,000	68,000	77,000	84,000	90,000
Head and neck	67,000	80,000	96,000	110,000	130,000	27,000	32,000	38,000	42,000	45,000
Lung	48,000	51,000	54,000	57,000	59,000	32,000	34,000	36,000	38,000	39,000
Urology, excl prostate	170,000	200,000	220,000	240,000	260,000	59,000	67,000	74,000	80,000	85,000
Upper GI	59,000	68,000	78,000	87,000	95,000	34,000	39,000	44,000	47,000	50,000
Brain/CNS	22,000	25,000	29,000	32,000	35,000	7,400	8,300	9,000	9,600	10,000
Sarcoma	15,000	16,000	18,000	19,000	20,000	3,800	4,000	4,400	4,700	4,900

England - All cancers combined		Complete cancer prevalence					5-year prevalence				
		2025	2030	2035	2040	2045	2025	2030	2035	2040	2045
Female	0-39	66,000	69,000	72,000	74,000	77,000	34,000	37,000	38,000	40,000	41,000
	40-49	110,000	120,000	130,000	140,000	140,000	51,000	59,000	65,000	67,000	67,000
	50-59	250,000	250,000	270,000	300,000	330,000	110,000	110,000	120,000	140,000	140,000
	60-69	390,000	470,000	500,000	500,000	540,000	150,000	180,000	190,000	190,000	200,000
	70-79	460,000	510,000	610,000	710,000	750,000	150,000	170,000	200,000	230,000	230,000
	80-89	300,000	390,000	440,000	490,000	590,000	88,000	110,000	130,000	140,000	170,000
	90+	59,000	74,000	97,000	130,000	140,000	17,000	20,000	25,000	31,000	34,000
Male	0-39	51,000	53,000	56,000	58,000	59,000	22,000	24,000	25,000	26,000	26,000
	40-49	53,000	59,000	65,000	69,000	72,000	22,000	25,000	28,000	31,000	32,000
	50-59	130,000	140,000	150,000	170,000	190,000	68,000	74,000	83,000	95,000	100,000
	60-69	270,000	320,000	350,000	360,000	390,000	140,000	170,000	180,000	190,000	190,000
	70-79	410,000	450,000	540,000	630,000	660,000	180,000	200,000	240,000	270,000	280,000
	80-89	280,000	360,000	400,000	450,000	540,000	96,000	120,000	140,000	150,000	180,000
	90+	43,000	56,000	76,000	100,000	110,000	12,000	15,000	20,000	26,000	28,000
Persons	0-39	120,000	120,000	130,000	130,000	140,000	56,000	60,000	63,000	65,000	67,000
	40-49	160,000	180,000	200,000	200,000	210,000	73,000	83,000	93,000	97,000	99,000
	50-59	380,000	390,000	420,000	480,000	520,000	180,000	190,000	200,000	230,000	250,000
	60-69	660,000	790,000	850,000	870,000	930,000	290,000	350,000	380,000	380,000	390,000
	70-79	880,000	960,000	1,200,000	1,300,000	1,400,000	330,000	370,000	450,000	500,000	510,000
	80-89	580,000	740,000	830,000	930,000	1,100,000	180,000	240,000	260,000	290,000	340,000
	90+	100,000	130,000	170,000	230,000	250,000	29,000	35,000	46,000	57,000	62,000

Scotland - Persons - All ages	Complete cancer prevalence					5-year prevalence				
	2025	2030	2035	2040	2045	2025	2030	2035	2040	2045
All cancers combined	310,000	350,000	390,000	420,000	460,000	120,000	140,000	150,000	160,000	170,000
Female breast	81,000	91,000	100,000	110,000	120,000	24,000	26,000	28,000	30,000	31,000
Prostate	48,000	60,000	72,000	83,000	92,000	21,000	26,000	29,000	31,000	32,000
Colorectal	37,000	41,000	45,000	49,000	52,000	14,000	15,000	16,000	17,000	18,000
Melanoma	24,000	29,000	35,000	41,000	46,000	7,700	9,700	11,000	13,000	14,000
Haematology	30,000	33,000	37,000	40,000	43,000	9,500	11,000	12,000	13,000	13,000
Gynaecology	29,000	32,000	35,000	38,000	41,000	7,800	8,800	9,700	10,000	11,000
Head and neck	17,000	19,000	21,000	23,000	25,000	5,500	6,000	6,500	6,900	7,100
Lung	17,000	20,000	23,000	25,000	28,000	10,000	12,000	14,000	15,000	15,000
Urology, excl prostate	24,000	27,000	30,000	33,000	35,000	8,300	9,400	10,000	11,000	12,000
Upper GI	11,000	13,000	14,000	16,000	17,000	6,000	6,800	7,600	8,200	8,500
Brain/CNS	3,200	3,600	4,000	4,300	4,600	980	1,000	1,100	1,100	1,200
Sarcoma *	2,600	3,000	3,400	3,700	4,100	700	810	900	970	1,000

* Due to a coding difference in the incidence data used to generate the estimates, sarcoma prevalence projections for Scotland are not directly comparable with those for other UK nations and are likely to underestimate the true prevalence of sarcoma in Scotland.

Scotland - Female - All ages	Complete cancer prevalence					5-year prevalence				
	2025	2030	2035	2040	2045	2025	2030	2035	2040	2045
All cancers combined	180,000	200,000	220,000	240,000	260,000	63,000	72,000	79,000	85,000	89,000
Female breast	81,000	91,000	100,000	110,000	120,000	24,000	26,000	28,000	30,000	31,000
Colorectal	18,000	20,000	23,000	25,000	28,000	6,700	7,600	8,300	8,900	9,300
Melanoma	14,000	16,000	19,000	22,000	25,000	3,900	4,700	5,400	6,000	6,300
Haematology	14,000	15,000	17,000	18,000	20,000	4,200	4,800	5,300	5,700	6,000
Gynaecology	29,000	32,000	35,000	38,000	41,000	7,800	8,800	9,700	10,000	11,000
Head and neck	9,300	11,000	12,000	14,000	15,000	2,800	3,100	3,400	3,600	3,800
Lung	10,000	12,000	15,000	18,000	20,000	6,100	7,600	9,100	10,000	10,000
Urology, excl prostate	6,200	7,000	7,900	8,700	9,500	2,400	2,700	3,000	3,300	3,500
Upper GI	4,400	5,000	5,700	6,300	6,800	2,300	2,500	2,800	3,000	3,200
Brain/CNS	1,400	1,500	1,700	1,800	1,900	<500	<500	<500	<500	<500
Sarcoma *	1,500	1,700	2,000	2,300	2,500	<500	<500	540	580	610

* Due to a coding difference in the incidence data used to generate the estimates, sarcoma prevalence projections for Scotland are not directly comparable with those for other UK nations and are likely to underestimate the true prevalence of sarcoma in Scotland.

Scotland - Male - All ages	Complete cancer prevalence					5-year prevalence				
	2025	2030	2035	2040	2045	2025	2030	2035	2040	2045
All cancers combined	130,000	150,000	170,000	180,000	200,000	57,000	65,000	73,000	78,000	81,000
Prostate	48,000	60,000	72,000	83,000	92,000	21,000	26,000	29,000	31,000	32,000
Colorectal	19,000	21,000	22,000	24,000	25,000	7,500	7,700	8,200	8,500	8,700
Melanoma	10,000	13,000	16,000	19,000	21,000	3,800	5,000	6,000	6,900	7,400
Haematology	16,000	18,000	20,000	22,000	23,000	5,300	6,100	6,700	7,200	7,500
Head and neck	7,600	8,200	8,700	9,200	9,700	2,700	2,900	3,100	3,300	3,300
Lung	6,800	7,000	7,300	7,500	7,700	4,100	4,300	4,500	4,600	4,700
Urology, excl prostate	18,000	20,000	22,000	24,000	26,000	5,900	6,600	7,300	7,700	8,000
Upper GI	6,600	7,600	8,600	9,500	10,000	3,800	4,300	4,800	5,100	5,300
Brain/CNS	1,800	2,100	2,300	2,500	2,700	580	640	680	710	720
Sarcoma *	1,100	1,200	1,300	1,500	1,600	<500	<500	<500	<500	<500

* Due to a coding difference in the incidence data used to generate the estimates, sarcoma prevalence projections for Scotland are not directly comparable with those for other UK nations and are likely to underestimate the true prevalence of sarcoma in Scotland.

Scotland - All cancers combined		Complete cancer prevalence					5-year prevalence				
		2025	2030	2035	2040	2045	2025	2030	2035	2040	2045
Female	0-39	6,300	6,500	6,500	6,600	6,700	3,300	3,500	3,500	3,600	3,600
	40-49	10,000	12,000	13,000	14,000	13,000	5,000	5,900	6,700	7,000	6,800
	50-59	26,000	25,000	27,000	31,000	34,000	12,000	11,000	12,000	14,000	15,000
	60-69	44,000	50,000	51,000	50,000	52,000	17,000	19,000	20,000	19,000	20,000
	70-79	52,000	57,000	67,000	75,000	75,000	16,000	18,000	22,000	24,000	23,000
	80-89	34,000	41,000	47,000	54,000	64,000	9,100	12,000	13,000	15,000	18,000
	90+	6,600	8,100	10,000	13,000	15,000	1,600	1,900	2,300	2,800	3,100
Male	0-39	4,700	4,800	5,000	5,000	5,000	2,000	2,100	2,200	2,200	2,200
	40-49	5,000	5,500	5,900	6,300	6,400	2,000	2,300	2,600	2,800	2,800
	50-59	13,000	13,000	13,000	15,000	17,000	6,400	6,500	7,100	8,300	9,300
	60-69	29,000	33,000	34,000	33,000	35,000	15,000	18,000	18,000	18,000	18,000
	70-79	44,000	50,000	59,000	65,000	65,000	20,000	23,000	27,000	29,000	28,000
	80-89	28,000	36,000	42,000	48,000	56,000	9,800	12,000	14,000	15,000	18,000
	90+	4,200	5,400	7,100	9,500	11,000	1,100	1,300	1,700	2,100	2,300
Persons	0-39	11,000	11,000	12,000	12,000	12,000	5,300	5,600	5,700	5,800	5,800
	40-49	15,000	17,000	19,000	20,000	20,000	7,000	8,100	9,300	9,700	9,600
	50-59	39,000	38,000	40,000	46,000	51,000	18,000	18,000	19,000	22,000	24,000
	60-69	73,000	83,000	85,000	83,000	87,000	32,000	37,000	38,000	36,000	38,000
	70-79	96,000	110,000	130,000	140,000	140,000	36,000	41,000	49,000	53,000	51,000
	80-89	62,000	77,000	89,000	100,000	120,000	19,000	24,000	27,000	31,000	35,000
	90+	11,000	13,000	17,000	22,000	26,000	2,800	3,200	4,000	4,900	5,500

Wales - Persons - All ages	Complete cancer prevalence					5-year prevalence				
	2025	2030	2035	2040	2045	2025	2030	2035	2040	2045
All cancers combined	180,000	200,000	220,000	240,000	260,000	68,000	77,000	85,000	91,000	95,000
Female breast	47,000	52,000	57,000	62,000	67,000	13,000	15,000	16,000	17,000	18,000
Prostate	34,000	39,000	46,000	51,000	56,000	12,000	15,000	17,000	18,000	18,000
Colorectal	21,000	24,000	26,000	28,000	30,000	8,400	9,100	9,800	10,000	11,000
Melanoma	14,000	18,000	22,000	25,000	29,000	5,000	6,300	7,500	8,400	9,000
Haematology	18,000	19,000	21,000	23,000	24,000	5,300	6,000	6,700	7,200	7,500
Gynaecology	17,000	19,000	20,000	22,000	24,000	4,600	5,100	5,600	5,900	6,200
Head and neck	8,500	9,700	11,000	12,000	13,000	2,800	3,100	3,400	3,700	3,900
Lung	7,100	8,200	9,400	11,000	11,000	4,500	5,200	5,900	6,300	6,600
Urology, excl prostate	14,000	14,000	15,000	16,000	17,000	4,200	4,500	4,800	5,100	5,300
Upper GI	6,700	7,600	8,500	9,400	10,000	3,700	4,200	4,600	5,000	5,200
Brain/CNS	2,900	3,200	3,500	3,800	4,000	810	850	920	970	1,000
Sarcoma	3,000	3,100	3,200	3,400	3,500	630	630	680	720	770

Wales - Female - All ages	Complete cancer prevalence					5-year prevalence				
	2025	2030	2035	2040	2045	2025	2030	2035	2040	2045
All cancers combined	100,000	110,000	120,000	130,000	140,000	35,000	40,000	44,000	47,000	49,000
Female breast	47,000	52,000	57,000	62,000	67,000	13,000	15,000	16,000	17,000	18,000
Colorectal	9,600	11,000	13,000	14,000	16,000	3,900	4,500	4,900	5,200	5,500
Melanoma	7,600	9,500	11,000	14,000	15,000	2,500	3,100	3,500	3,900	4,200
Haematology	7,800	8,500	9,300	10,000	11,000	2,200	2,500	2,800	3,000	3,100
Gynaecology	17,000	19,000	20,000	22,000	24,000	4,600	5,100	5,600	5,900	6,200
Head and neck	4,300	5,000	5,700	6,400	7,100	1,300	1,400	1,600	1,700	1,800
Lung	4,100	5,100	6,200	7,200	8,000	2,600	3,200	3,800	4,200	4,400
Urology, excl prostate	3,200	3,300	3,500	3,700	4,000	1,000	1,100	1,200	1,300	1,400
Upper GI	2,800	3,200	3,700	4,000	4,400	1,500	1,700	1,900	2,000	2,200
Brain/CNS	1,400	1,500	1,600	1,700	1,900	<500	<500	<500	<500	<500
Sarcoma	1,900	2,000	2,100	2,100	2,200	<500	<500	<500	<500	<500

Wales - Male - All ages	Complete cancer prevalence					5-year prevalence				
	2025	2030	2035	2040	2045	2025	2030	2035	2040	2045
All cancers combined	80,000	89,000	99,000	110,000	120,000	33,000	37,000	41,000	44,000	46,000
Prostate	34,000	39,000	46,000	51,000	56,000	12,000	15,000	17,000	18,000	18,000
Colorectal	12,000	12,000	13,000	14,000	14,000	4,500	4,700	4,900	5,100	5,300
Melanoma	6,400	8,100	10,000	12,000	14,000	2,500	3,200	3,900	4,400	4,800
Haematology	9,900	11,000	12,000	13,000	14,000	3,000	3,500	3,900	4,200	4,400
Head and neck	4,200	4,700	5,200	5,800	6,300	1,600	1,700	1,800	2,000	2,100
Lung	3,000	3,000	3,200	3,300	3,300	1,900	2,000	2,100	2,200	2,200
Urology, excl prostate	10,000	11,000	12,000	12,000	13,000	3,100	3,400	3,600	3,800	3,900
Upper GI	3,900	4,400	4,900	5,300	5,700	2,200	2,500	2,700	2,900	3,100
Brain/CNS	1,500	1,700	1,800	2,000	2,200	<500	<500	530	560	580
Sarcoma	1,100	1,100	1,200	1,200	1,300	<500	<500	<500	<500	<500

Wales - All cancers combined		Complete cancer prevalence					5-year prevalence				
		2025	2030	2035	2040	2045	2025	2030	2035	2040	2045
Female	0-39	3,600	3,900	4,000	4,000	4,100	1,800	2,000	2,000	2,100	2,100
	40-49	5,500	6,300	7,100	7,700	7,800	2,700	3,100	3,600	3,800	3,800
	50-59	14,000	13,000	14,000	16,000	18,000	6,100	6,000	6,300	7,200	8,100
	60-69	24,000	27,000	28,000	27,000	28,000	8,700	10,000	10,000	10,000	10,000
	70-79	31,000	32,000	37,000	42,000	42,000	9,300	10,000	12,000	13,000	13,000
	80-89	21,000	26,000	28,000	30,000	36,000	5,600	7,100	8,000	8,600	9,900
	90+	3,900	4,800	6,400	8,200	9,000	1,000	1,200	1,500	1,900	2,000
Male	0-39	3,000	3,100	3,200	3,200	3,300	1,200	1,300	1,400	1,400	1,400
	40-49	3,000	3,400	3,700	4,000	4,100	1,200	1,400	1,600	1,800	1,800
	50-59	7,200	7,200	7,700	8,900	10,000	3,500	3,700	3,900	4,600	5,300
	60-69	17,000	19,000	20,000	20,000	20,000	8,500	10,000	11,000	10,000	10,000
	70-79	28,000	29,000	33,000	37,000	38,000	11,000	12,000	15,000	16,000	16,000
	80-89	19,000	24,000	26,000	28,000	33,000	6,000	7,500	8,100	8,800	10,000
	90+	3,000	3,800	5,100	6,600	7,200	740	920	1,200	1,500	1,600
Persons	0-39	6,600	6,900	7,200	7,300	7,300	3,000	3,300	3,400	3,500	3,500
	40-49	8,500	9,700	11,000	12,000	12,000	3,900	4,500	5,200	5,600	5,700
	50-59	21,000	21,000	22,000	25,000	28,000	9,700	9,700	10,000	12,000	13,000
	60-69	40,000	46,000	47,000	46,000	48,000	17,000	20,000	21,000	20,000	21,000
	70-79	59,000	61,000	70,000	79,000	80,000	21,000	23,000	27,000	29,000	29,000
	80-89	40,000	49,000	54,000	59,000	68,000	12,000	15,000	16,000	17,000	20,000
	90+	6,900	8,700	11,000	15,000	16,000	1,800	2,100	2,700	3,400	3,600

Northern Ireland - Persons - All ages	Complete cancer prevalence					5-year prevalence				
	2025	2030	2035	2040	2045	2025	2030	2035	2040	2045
All cancers combined	93,000	110,000	120,000	140,000	150,000	37,000	43,000	49,000	53,000	56,000
Female breast	24,000	27,000	31,000	35,000	38,000	7,400	8,400	9,200	9,800	10,000
Prostate	16,000	20,000	25,000	29,000	33,000	6,900	8,500	10,000	11,000	12,000
Colorectal	11,000	13,000	14,000	16,000	18,000	4,600	5,100	5,600	6,000	6,300
Melanoma	6,800	8,500	10,000	12,000	14,000	2,300	2,900	3,500	4,000	4,300
Haematology	9,500	11,000	12,000	14,000	15,000	3,200	3,700	4,200	4,600	4,900
Gynaecology	9,000	10,000	11,000	12,000	13,000	2,300	2,600	2,900	3,100	3,200
Head and neck	5,300	6,400	7,600	8,800	9,900	1,800	2,200	2,500	2,700	2,900
Lung	3,800	4,500	5,300	6,100	6,600	2,500	3,000	3,400	3,800	4,000
Urology, excl prostate	7,000	8,000	8,900	9,800	11,000	2,400	2,700	3,100	3,300	3,500
Upper GI	3,200	3,700	4,300	4,900	5,300	1,800	2,100	2,400	2,600	2,800
Brain/CNS	1,400	1,600	1,700	1,900	2,100	<500	<500	520	540	560
Sarcoma	1,300	1,400	1,600	1,700	1,800	<500	<500	<500	<500	<500

Northern Ireland - Female - All ages	Complete cancer prevalence					5-year prevalence				
	2025	2030	2035	2040	2045	2025	2030	2035	2040	2045
All cancers combined	53,000	61,000	70,000	77,000	84,000	19,000	22,000	25,000	27,000	28,000
Female breast	24,000	27,000	31,000	35,000	38,000	7,400	8,400	9,200	9,800	10,000
Colorectal	5,200	6,200	7,200	8,200	9,200	2,200	2,500	2,800	3,000	3,200
Melanoma	4,100	5,000	5,900	6,900	7,800	1,200	1,500	1,700	1,900	2,000
Haematology	4,200	4,800	5,400	6,100	6,700	1,400	1,600	1,800	2,000	2,100
Gynaecology	9,000	10,000	11,000	12,000	13,000	2,300	2,600	2,900	3,100	3,200
Head and neck	3,200	4,000	4,900	5,800	6,600	1,100	1,300	1,500	1,600	1,700
Lung	2,100	2,700	3,400	4,000	4,500	1,400	1,800	2,200	2,400	2,600
Urology, excl prostate	1,700	2,000	2,200	2,500	2,800	670	770	870	950	1,000
Upper GI	1,300	1,500	1,700	2,000	2,200	690	800	910	1,000	1,100
Brain/CNS	620	700	780	860	930	<500	<500	<500	<500	<500
Sarcoma	830	940	1,100	1,200	1,300	<500	<500	<500	<500	<500

Northern Ireland - Male - All ages	Complete cancer prevalence					5-year prevalence				
	2025	2030	2035	2040	2045	2025	2030	2035	2040	2045
All cancers combined	39,000	46,000	53,000	60,000	66,000	18,000	21,000	24,000	26,000	27,000
Prostate	16,000	20,000	25,000	29,000	33,000	6,900	8,500	10,000	11,000	12,000
Colorectal	5,900	6,600	7,200	7,800	8,300	2,500	2,600	2,800	3,000	3,100
Melanoma	2,700	3,500	4,500	5,400	6,200	1,100	1,400	1,800	2,100	2,300
Haematology	5,300	6,100	7,000	7,800	8,400	1,800	2,200	2,500	2,700	2,800
Head and neck	2,100	2,400	2,700	3,000	3,300	760	880	1,000	1,100	1,200
Lung	1,700	1,800	1,900	2,000	2,100	1,100	1,200	1,300	1,400	1,400
Urology, excl prostate	5,400	6,000	6,700	7,300	7,800	1,800	2,000	2,200	2,400	2,500
Upper GI	1,900	2,200	2,600	2,900	3,200	1,100	1,300	1,500	1,600	1,700
Brain/CNS	750	850	960	1,100	1,200	<500	<500	<500	<500	<500
Sarcoma	<500	<500	510	530	540	<500	<500	<500	<500	<500

NI - All cancers combined		Complete cancer prevalence					5-year prevalence				
		2025	2030	2035	2040	2045	2025	2030	2035	2040	2045
Female	0-39	2,400	2,400	2,400	2,500	2,600	1,200	1,200	1,200	1,300	1,300
	40-49	3,700	4,200	4,400	4,300	4,100	1,700	1,900	2,000	2,000	1,900
	50-59	8,300	8,400	9,100	10,000	11,000	3,600	3,700	4,000	4,400	4,600
	60-69	13,000	16,000	17,000	17,000	18,000	5,100	6,100	6,400	6,500	6,700
	70-79	15,000	17,000	21,000	24,000	25,000	4,600	5,500	6,700	7,600	7,600
	80-89	9,400	12,000	14,000	16,000	20,000	2,700	3,400	3,900	4,600	5,400
	90+	1,700	2,200	2,900	3,700	4,400	<500	540	700	840	960
Male	0-39	1,600	1,600	1,700	1,700	1,800	660	690	710	740	760
	40-49	1,600	1,700	1,800	1,800	1,900	600	670	740	750	750
	50-59	4,000	4,100	4,300	4,800	5,200	2,000	2,200	2,400	2,700	2,900
	60-69	8,900	10,000	11,000	11,000	12,000	4,800	5,800	6,200	6,200	6,400
	70-79	14,000	16,000	19,000	22,000	23,000	6,300	7,400	8,900	10,000	10,000
	80-89	8,600	11,000	13,000	15,000	19,000	3,000	3,700	4,300	5,000	5,900
	90+	1,200	1,700	2,300	3,000	3,600	<500	<500	570	690	790
Persons	0-39	3,900	4,000	4,000	4,200	4,300	1,800	1,900	1,900	2,000	2,100
	40-49	5,200	5,900	6,200	6,100	6,000	2,300	2,600	2,800	2,700	2,600
	50-59	12,000	12,000	13,000	15,000	16,000	5,700	5,900	6,400	7,100	7,400
	60-69	22,000	26,000	28,000	28,000	30,000	9,900	12,000	13,000	13,000	13,000
	70-79	28,000	33,000	40,000	46,000	48,000	11,000	13,000	16,000	18,000	18,000
	80-89	18,000	23,000	27,000	31,000	38,000	5,700	7,100	8,200	9,600	11,000
	90+	2,900	3,900	5,200	6,700	8,000	790	970	1,300	1,500	1,700

Data sources

- Cancer Registrations for England (1971-2021; NHS England, NHS Digital, Public Health England and ONS)
- Cancer Incidence for Scotland (1998-2022; Public Health Scotland)
- Cancer Incidence for Wales (1992-2022; Public Health Wales)
- Cancer Incidence for Northern Ireland (1993-2022); Queens University Belfast)
- Cancer Survival for England (2001-2020; NHS England, NHS Digital, Public Health England and ONS)
- Cancer survival for England and Wales articles (1986-2001; British Journal of Cancer, 2008)
- Cancer Survival for Scotland (1993-2017; Public Health Scotland)
- Cancer Prevalence for England (2021; NDRS)
- Cancer Prevalence for Scotland (2019-2022; Public Health Scotland)
- Population estimates for the four nations (1970-2024; ONS)
- Population projections for the four nations (2022-2025; ONS)
- General population mortality (1980-2020; ONS)
- Projected background mortality (Scottish Widows' actuarial modelling)

Cancer types lookup

The following mapping of ICD-10 to cancer type was used throughout and in each constituent nation.

All cancers combined:	C00-C97, excluding C44
Brain/CNS:	C69-C72
Female breast:	C50
Colorectal:	C18-C20
Gynaecology:	C51-C58
Haematology:	C81-C86, C88, C90-C96
Head and neck:	C00-C14, C30-C32, C73
Lung:	C33-34, C39, C45
Melanoma:	C43
Prostate:	C61
Sarcoma:	C40-C41, C47-C49
Upper GI:	C15-C17, C22-C25
Urology, excl prostate:	C60, C62-C68

Acknowledgements

This work uses data provided by people living with cancer and collected by the NHS and others as part of their care and support. We would like to thank the people living with cancer who have given us their data and made this possible.